west china medical publishers
Keyword
  • Title
  • Author
  • Keyword
  • Abstract
Advance search
Advance search

Search

find Keyword "早泄" 2 results
  • Effectiveness and Safety of Fluoxetine for Premature Ejaculation: A Meta-Analysis

    Objective To systematically evaluate the effectiveness and safety of fluoxetine in treating premature ejaculation (PE). Methods All randomized controlled trials (RCTs) on fluoxetine treating PE published from July 1996 to May 2012 were collected in the following databases: MEDLINE, EMbase, PubMed, Ovid, The Cochrane Central Register of Controlled Trials, CBM and CKNI. According to the inclusion and exclusion criteria, literature screening, data extraction and quality assessment were conducted independently by two reviewers. Then meta-analysis was performed using RevMan 5.0 software. Results A total of 6 RCTs involving 221 patients were included finally. The results of meta-analysis showed that, as for effectiveness, there was no significant difference in the intravaginal ejaculatory latency time (IELT) between the two groups before the treatment (WMD=–0.21, 95%CI −4.79 to 4.37, P=0.93), but the IELT of the fluoxetine group was obviously longer than that of the control group after the treatment, with a significant difference (WMD=134.54, 95%CI 79.78 to 189.30, Plt;0.000 01). The results of sensitivity analysis indicated that the IELT of the fluoxetine group was longer than that of the control group, with a significant difference (WMD=155.19, 95%CI 130.64 to 179.75, Plt;0.000 01). As for safety, the fluoxetine group was higher in the incidence of adverse reaction than the control group, with a significant difference (OR=5.49, 95%CI 2.43 to 12.38, Plt;0.000 1). Conclusion Current evidence indicates that fluoxetine can improve the symptoms of PE patients, obviously prolong the IELT, and improve the quality of sexual life; and it is tolerable to patients with mild adverse reactions and is suitable for long-term intake. For the limited quantity of the included studies, we herein believe that, to obtain more evidence, it is necessary to further confirm the diagnosis and therapeutic criteria of PE, to design and conduct more multicenter and large scale clinical studies by adopting the internationally recognized indexes, and to perform a long-term follow-up.

    Release date:2016-08-25 02:39 Export PDF Favorites Scan
  • 早泄的药物治疗进展

    早泄是最常见的男性性功能障碍,药物一直是早泄治疗的焦点。选择性5-羟色胺再摄取抑制剂(SSRIs)是目前临床证据最多、应用最广泛的药物,其中达泊西汀是唯一被批准用于治疗早泄的短效SSRI;局部麻醉药物疗效确切,可按需使用,且不良反应少,是治疗早泄的理想药物;α1-肾上腺素能受体阻滞剂、5型磷酸二酯酶抑制剂、曲马多的有效性和安全性尚缺乏大量确切临床证据,今后有望成为治疗早泄的新方法。随着对生理性射精过程和相关神经递质的深入研究,将会为早泄的药物治疗提供新的思路和选择。

    Release date: Export PDF Favorites Scan
1 pages Previous 1 Next

Format

Content